GoAI
Get started
Larimar Therapeutics, Inc. logo

Larimar Therapeutics, Inc.

LRMR

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$4.18

+$0.02 · +0.48%

Aug 21, 4:00 PM ET

LRMR company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

31

Expensive

Momentum

71

Gaining

Sentiment

54

Mixed

Risk resilience

41

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Carole S. Ben-Maimon
Listed since
Jun 19, 2014
Employees
71

Market position

Day range

Current $4.18

52-week range

Current $4.18

Open
$4.16
Previous close
$4.16
Volume
699.42K
0.37× average
Average volume
1.89M
Average daily volume
Market cap
434.23M USD
Beta
0.75
Market reference 1
50-day average
$3.82
+9.42% above average
200-day average
$3.9067
+7.00% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
196.59M USD
P/E (TTM)
-2.1×
P/B (TTM)
3.41×
P/S (TTM)
0×
EV / EBITDA
-1.19×
Earnings yield
-59.61%
Free cash flow yield
-40.76%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-212.17%
Return on assets
-113.60%
Return on invested capital
-209.97%

Financial health

Debt / equity
0.04×
Current ratio
2.19×

Financial statements

Income trends

Operating income

−172.5M USD-89.79%

Net income

−165.67M USD-105.54%
Income trends across reported periods−21.64M USD−76.5M USD−131.35M USD−186.21M USDOperating income, FY2021: −50.47M USDOperating income, FY2022: −36.53M USDOperating income, FY2023: −41.76M USDOperating income, FY2024: −90.89M USDOperating income, FY2025: −172.5M USDNet income, FY2021: −50.64M USDNet income, FY2022: −35.36M USDNet income, FY2023: −36.95M USDNet income, FY2024: −80.6M USDNet income, FY2025: −165.67M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −50.47M USD. Operating income FY2022 −36.53M USD. Operating income FY2023 −41.76M USD. Operating income FY2024 −90.89M USD. Operating income FY2025 −172.5M USD. Net income FY2021 −50.64M USD. Net income FY2022 −35.36M USD. Net income FY2023 −36.95M USD. Net income FY2024 −80.6M USD. Net income FY2025 −165.67M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Research and development154.22M USD73.28M USD27.67M USD24.25M USD38.4M USD
Selling, general, and administrative18.27M USD17.61M USD14.09M USD12.28M USD12.07M USD
Operating expenses172.5M USD90.89M USD41.76M USD36.53M USD50.47M USD
Depreciation and amortization350K USD318K USD311K USD318K USD326K USD
Operating income−172.5M USD−90.89M USD−41.76M USD−36.53M USD−50.47M USD
Net income−165.67M USD−80.6M USD−36.95M USD−35.36M USD−50.64M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
36%
4 beats, 7 misses, 0 met estimates
Average EPS surprise
-10.45%
11 comparable reports
Latest EPS result
-0.3
Estimate -0.38 · Beat by 21.35%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.25-0.42-0.6-0.77Q1 '25MissQ2 '25MissQ3 '25BeatQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 24, 2025: actual -0.45, estimate -0.29, surprise -55.17%, Miss. Q2 2025, reported Apr 30, 2025: actual -0.46, estimate -0.42, surprise -9.52%, Miss. Q3 2025, reported Aug 14, 2025: actual -0.41, estimate -0.47, surprise +12.77%, Beat. Q4 2025, reported Nov 5, 2025: actual -0.61, estimate -0.39, surprise -56.41%, Miss. Q1 2026, reported Mar 19, 2026: actual -0.73, estimate -0.44, surprise -65.91%, Miss. Q2 2026, reported May 14, 2026: actual -0.31, estimate -0.53, surprise +41.51%, Beat. Q3 2026, reported Aug 4, 2026: actual -0.3, estimate -0.381, surprise +21.35%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate -0.39, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

8 ratings
Strong buy00%
Buy8100%
Hold00%
Sell00%
Strong sell00%

LRMR news

defenseworld.net

Dimensional Fund Advisors LP Purchases 470,968 Shares of Larimar Therapeutics, Inc. $LRMR

Dimensional Fund Advisors LP lifted its position in shares of Larimar Therapeutics, Inc. (NASDAQ: LRMR) by 143.8% during the first quarter, according to the company in its most recent filing with the Securities and…

Read source
globenewswire.com

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

BALA CYNWYD, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported…

Read source
prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

NEW YORK, July 23, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or the "Company") (NASDAQ: LRMR). Such investors are advised to contact…

Read source
globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. (“Larimar” or the “Company”) (NASDAQ: LRMR). Such investors are advised to contact…

Read source
prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

NEW YORK , July 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or the "Company") (NASDAQ: LRMR). Such investors are advised to contact…

Read source
globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. (“Larimar” or the “Company”) (NASDAQ: LRMR). Such investors are advised to contact…

Read source

Corporate actions

Corporate action history

Stock split

Effective May 29, 2020

1:12

LRMR peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding LRMR

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
8.43M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
7.06M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Fidelity Enhanced Small Cap ETF logoFidelity Enhanced Small Cap ETFFESM
Market value
3.86M
Weight
0.06%
AUM
6.03B USD
Expense ratio
0.28%
Price / 1D
$47.94+0.80%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
2.67M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
2.6M
Weight
0.02%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
1.62M
Weight
0.02%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
1.43M
Weight
0.01%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
Dimensional - US Small Cap ETF logoDimensional - US Small Cap ETFDFAS
Market value
1.42M
Weight
0.01%
AUM
15.92B USD
Expense ratio
0.26%
Price / 1D
$83.02+0.73%

Continue in GoAI

Research LRMR

research.disclaimer